Novogene
C2i Genomics, NovogeneAIT Genomics Partner to Launch Cancer Detection Platform in Southeast Asia
C2i's platform uses artificial intelligence pattern recognition and whole-genome analysis to detect minimal residual disease in blood samples from cancer patients.
Novogene, Chipscreen Ink CDx Development Deal
Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.
In Brief This Week: Hologic, Novogene, and Agilent Technologies
Hologic said this week that it has opened a Learning and Experience Centre in Zaventem, Belgium. The 1,500-square-meter facility provides training for customers, healthcare professionals, and employees across its Europe, Middle East, and Africa region.
China FDA Approves Novogene CDx Test for NSCLC Therapies
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
Lucence, NovogeneAIT Genomics Singapore Ink Precision Cancer Medicine Alliance
The partners will develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.